Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1(G2032R) and ALK(G1202R)

Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the clinical effects of Crizotinib. To combat drug resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Siming, Huang, Chuan, Huang, Chunhui, Huang, Yaqi, Yu, Yonghuan, Wu, Guowu, Guo, Fengqiu, Jiang, Ying, Wan, Shanhe, Zhu, Zhengguang, Tian, Yuanxin, Zhu, Jianghua, Zhang, Jiajie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288926/
https://www.ncbi.nlm.nih.gov/pubmed/37349867
http://dx.doi.org/10.1080/14756366.2023.2227779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288926/
https://www.ncbi.nlm.nih.gov/pubmed/37349867
http://dx.doi.org/10.1080/14756366.2023.2227779

Ejemplares similares